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IMPORTANCE Associations between atopic eczema and cancer are unclear, with competing
theories that increased immune surveillance decreases cancer risk and that immune
stimulation increases cancer risk. Establishing baseline cancer risk in people with atopic
eczema is important before exploring the association between new biologic drugs for atopic
eczema and cancer risk.
OBJECTIVE To investigate whether atopic eczema is associated with cancer.
DESIGN, SETTING, AND PARTICIPANTS Matched cohort studies were conducted from January
2, 1998, to March 31, 2016, in England and from January 1, 1982, to June 30, 2016, in
Denmark. We conducted our analyses between July 2018 and July 2019. The setting was
English primary care and nationwide Danish data. Participants with atopic eczema (adults
only in England and any age in Denmark) were matched on age, sex, and calendar period (as
well as primary care practice in England only) to those without atopic eczema.
EXPOSURE Atopic eczema.
MAIN OUTCOMES AND MEASURES Overall cancer risk and risk of specific cancers were
compared in people with and without atopic eczema.
RESULTS In England, matched cohorts included 471 970 individuals with atopic eczema
(median [IQR] age, 41.1 [24.9-60.7] years; 276 510 [58.6%] female) and 2 239 775 individuals
without atopic eczema (median [IQR] age, 39.8 [25.9-58.4] years; 1 301 074 [58.1%] female).
In Denmark, matched cohorts included 44 945 individuals with atopic eczema (median [IQR]
age, 13.7 [1.7-21.1] years; 22 826 [50.8%] female) and 445 673 individuals without atopic
eczema (median [IQR] age, 13.5 [1.7-20.8] years; 226 323 [50.8%] female). Little evidence
was found of associations between atopic eczema and overall cancer (adjusted hazard ratio
[HR], 1.04; 99% CI, 1.02-1.06 in England and 1.05; 99% CI, 0.95-1.16 in Denmark) or for most
specific cancers. However, noncutaneous lymphoma risk was increased in people with atopic
eczema in England (adjusted HR, 1.19; 99% CI, 1.07-1.34 for non-Hodgkin lymphoma [NHL]
and 1.48; 99% CI, 1.07-2.04 for Hodgkin lymphoma). Lymphoma risk was increased in people
with greater eczema severity vs those without atopic eczema (NHL adjusted HR, 1.06; 99%
CI, 0.90-1.25 for mild eczema; 1.24; 99% CI, 1.04-1.48 for moderate eczema; and 2.08; 99%
CI, 1.42-3.04 for severe eczema). Danish point estimates also showed increased lymphoma
risk in people with moderate to severe eczema compared with those without atopic eczema
(minimally adjusted HR, 1.31; 99% CI, 0.76-2.26 for NHL and 1.35; 99% CI, 0.65-2.82 for
Hodgkin lymphoma), but the 99% CIs were wide.
CONCLUSIONS AND RELEVANCE The findings from 2 large population-based studies performed
in different settings do not support associations between atopic eczema and most cancers.
However, an association was observed between atopic eczema and lymphoma, particularly
NHL, that increased with eczema severity. This finding warrants further study as new
immunomodulatory systemic therapeutics are brought to market that may alter cancer risk.
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A topic eczema is the most common inflammatory skindisease, affecting 2% to 10% of adults1-3 and up to 20%of children.4 Eczema may be associated with cancer for
many reasons, including immune dysregulation related to ec-
zema, unhealthy lifestyle choices (eg, smoking and alcohol con-
sumption as coping mechanisms for persistent itch), stress, low
self-esteem, and sleep deprivation.5,6 Although most eczema
is managed with topical treatment, systemic treatments (eg,
glucocorticoids, azathioprine, and cyclosporine) for severe dis-
ease could also affect cancer risk.7
Cancer is 1 of the leading causes of death globally.8 Skin
disease is the most common reason for a new primary care prac-
tice consultation in England,9,10 and eczema accounts for a sub-
stantial proportion of that burden.9 Hence, any association be-
tween atopic eczema and cancer is potentially relevant to public
health. Furthermore, as new therapeutics (that may alter can-
cer risk) are introduced, it is important to establish baseline
cancer risk in people with atopic eczema.11
A recent systematic review and meta-analysis12 high-
lighted that existing evidence of cancer risk in atopic eczema
is conflicting, with studies limited by lack of consideration of
eczema severity and treatment and by the inability to adjust
for key confounders. Studies have reported reductions in spe-
cific brain cancers and increased lymphoma risk in people with
eczema.5,6,13-19 Two competing theories may explain the com-
plex association between atopic eczema and cancer, namely,
that increased immune surveillance decreases cancer risk and
that immune stimulation increases cancer risk. Immunosup-
pressive therapy (including topical calcineurin inhibitors) and
an impaired skin barrier may also increase risk, particularly of
skin cancer, but recent findings are inconclusive.20 Experi-
mental mouse models support reduced skin cancer in indi-
viduals with atopic eczema,21 but population-based studies are
conflicting.6,22-25
We used health care data from matched cohort studies con-
ducted in England and Denmark to address uncertainties iden-
tified by the recent systematic review and meta-analysis.12 We
explored cancer risk in persons with atopic eczema com-
pared with those without atopic eczema, including variation
in risk with eczema severity and activity.
Methods
This investigation was composed of 2 matched cohort stud-
ies conducted from January 2, 1998, to March 31, 2016, in En-
gland and from January 1, 1982, to June 30, 2016, in Den-
mark. We conducted our analyses between July 2018 and July
2019. Participants with atopic eczema (adults only in En-
gland and any age in Denmark) were matched on age, sex, and
calendar period (as well as primary care practice in England
only) to people without atopic eczema. We compared overall
cancer risk and risk of specific cancers in those with and with-
out atopic eczema. The English study was approved by the Lon-
don School of Hygiene and Tropical Medicine Research Eth-
ics Committee and by the United Kingdom Clinical Practice
Research Datalink (CPRD) Independent Scientific Advisory
Committee (protocol 17_108). The English trial protocol is avail-
able at Supplement 1. The Danish study was approved by the
Danish Data Protection Agency (record 2015-57-0002; AU-
2016-051-000001; 632). The Danish trial protocol is available
at Supplement 2. These are deidentified data and do not re-
quire explicit consent; individual consent for use of elec-
tronic health record data for research is implied. In England,
individuals are offered the right to opt out of the use of their
anonymized data. Danish legislation does not require ap-
proval by an ethical review board or informed consent from
participants in registry-based studies.
Two matched cohorts of people with and without atopic
eczema in England and Denmark were identified (Table 1 and
Figure 1). We did not include children in the English study (un-
like the Danish study, in which we did not restrict age) be-
cause of limited power to study childhood cancers. Child-
hood cancer is rare, and the median follow-up in the CPRD is
only 5 years.26
Data Sources
In England, electronic health records of adults attending pri-
mary care practices contributing to the CPRD GOLD were used
along with linked hospital admissions (Hospital Episode Sta-
tistics [HES]) and death registration (Office for National Sta-
tistics [ONS]) data. The CPRD includes data from participat-
ing primar y c are practices covering 7% of the UK
population.26-28 The HES covers all admissions for National
Health Service–funded patients treated in England.29 Most Eng-
lish primary care practices contributing to the CPRD (75%) are
linked to the HES.26 The ONS mortality data include cause of
death for all deaths in the UK.
In Denmark, linked nationwide data from the Danish Na-
tional Patient Registry (hospital admissions, outpatient clinic
appointments, and emergency department contacts),30,31 the
Danish Cancer Registry (incident cancers),32 the Civil Regis-
tration System (demographics),33 the Danish National Pre-
scription Registry (prescriptions filled at community
pharmacies),34 and socioeconomic data were used. The socio-
economic data included highest educational level and gross
personal income gathered by Statistics Denmark.35,36
Morbidity code lists and additional details of all variable
definitions are provided in eAppendix 1 and eTables 16, 17, and
Key Points
Question Is atopic eczema associated with increased cancer risk?
Findings In 2 large cohort studies conducted in England (471 970
and 2 239 775 individuals with and without atopic eczema,
respectively) and Denmark (44 945 and 445 673 individuals with
and without atopic eczema, respectively), no evidence was found
of an increased risk of most cancers among people with atopic
eczema compared with those without eczema. However, atopic
eczema was associated with an increased risk of lymphoma,
particularly non-Hodgkin lymphoma, with risk increasing with
greater eczema severity.
Meaning The findings in this study did not support an association
between atopic eczema and most cancers; however, there was
evidence of higher lymphoma risk with increasing eczema severity.
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18 in Supplement 3. Complete code lists for all variables used
in the English study are available online.37
Study Cohorts, Exposure, and Outcomes
England
All adults (aged ≥18 years) registered with primary care prac-
tices contributing data meeting CPRD quality control stan-
dards between 1998 and 2016 were eligible for inclusion
(Figure 1 and eAppendix 2 in Supplement 3). Individuals
needed at least 1 year of registration before cohort entry. In-
dividuals with atopic eczema were identified based on a pre-
viously validated algorithm (eAppendix 1 in Supplement 3).38
We randomly selected an individually matched cohort (with-
out replacement) of up to 5 people for each individual with
atopic eczema by age, sex, and primary care practice (eAppen-
dix 2 in Supplement 3).
Denmark
All individuals (any age) born in Denmark with a hospital-
based (outpatient and inpatient records) diagnosis of atopic ec-
zema (mostly moderate to severe eczema) between 1982 and
2016 were identified (Figure 1 and eAppendix 2 in Supple-
ment 3). Also identified was a comparison cohort (with re-
placement) of up to 10 people without atopic eczema matched
to each individual with atopic eczema by sex and exact birth
year.39
Exclusions
In England and Denmark, we excluded individuals with any
history of cancer (except nonmelanoma skin cancer [NMSC]
or keratinocyte cancer). In analyses focused specifically on skin
cancer, we further excluded individuals with a previous NMSC
record.
Table 1. Summary of English and Danish Study Designs
Variable England Denmark
Sampling frame Individuals ≥18 y registered with primary care practices
contributing to the CPRD GOLD and eligible for linkage with
hospital record data between January 2, 1998, and March 31,
2016. The CPRD is broadly representative of the whole
population. We did not include children in the English study
(unlike the Danish study, in which we did not restrict on age)
because of limited power to study childhood cancers
(childhood cancer is rare, and the median follow-up in
the CPRD is only 5 y26).
All individuals (no age restriction) born and living in Denmark
between January 1, 1982, and June 30, 2016
Atopic eczema
definition
Atopic eczema identified based on a record of 1 atopic eczema
diagnostic code recorded in primary or secondary care and ≥2
primary care records (diagnosis code or prescription) for
atopic eczema therapy
Atopic eczema identified based on an atopic eczema diagnosis,
recorded as part of a hospital admission, emergency department
contact, or an outpatient appointment. Therefore, the Danish
cohort included people with more severe disease than the English
cohort because it was based on hospital diagnoses only.
Comparison
population
A cohort of individuals without atopic eczema matched on age
(within 15 y), sex, calendar period, and primary care practice.
We randomly matched (without replacement) up to
5 individuals without atopic eczema for every individual with
atopic eczema in calendar date order (ie, individuals in the
matched cohort were assigned first to those with earliest cohort
entry to avoid time-related bias). Individuals were censored and
no longer included in the comparison population on the date of
their first atopic eczema diagnosis (they were subsequently
included in the atopic eczema cohort if they also had ≥2 records
for atopic eczema therapies).
A cohort of up to 10 individuals matched (with replacement) on
sex and exact birth year to each individual with atopic eczema.
Individuals included in the matched cohort were Danish residents
who were born in Denmark and had no previous atopic eczema
diagnosis on the date of the first recorded atopic eczema diagnosis
(index date) of their matched atopic eczema–exposed individual.
In Denmark, we were able to match with up to 10 individuals
(rather than up to 5 in England) because we matched with
replacement
and did not match on primary care practice.
Cohort entry date
(index date)
Prevalent cohort of atopic eczema-exposed individuals entered
the cohort (index date) on the latest of 1 y after the date of
registration with their primary care practice, the date that the
practice met CPRD quality control standards, the start of the
study (January 2, 1998), their 18th birthday, or 12 mo from
the date of atopic eczema diagnosis (to limit potential reverse
causality)
New hospital diagnosis cohort individuals entered the cohort
(index date) on the date of their first atopic eczema diagnosis,
recorded either as part of a hospital admission or an outpatient
appointment
Cohort exit date Earliest of the following events: death, individual no longer
registered with the practice, practice no longer contributing
data to the CPRD, end of study (March 31, 2016), diagnosis of
atopic eczema (matched cohort only), or first-ever cancer
diagnosis (excluding nonmelanoma skin cancer)
Earliest of the following events: death, emigration, diagnosis of
atopic eczema (matched cohort only), first-ever cancer diagnosis
(excluding nonmelanoma skin cancer), or end of study (June 30,
2016)
Cancer definition Identified based on morbidity codes recorded in primary care
(CPRD) or as part of a hospital admission (HES) and cause of
death coding in ONS data
Identified based on diagnosis codes recorded in the Danish Cancer
Registry
Confounders
considered
Age, sex, calendar period, and IMD (as a proxy for
socioeconomic deprivation)
Age and sex. Highest educational level, partner status, and gross
personal income were used as proxies for socioeconomic status in
people 30 y or older only (because these measures are likely to be
incomplete for those aged <30 y).
Mediators considered Lifestyle factors, including BMI, smoking, and harmful
alcohol use
Because data on lifestyle variables were not available in Denmark,
we used diagnoses or treatments for diseases associated with
lifestyle factors as proxies, including chronic obstructive
pulmonary disease, hyperlipidemia, hypertension, alcohol-related
conditions, ischemic heart disease, hospital-diagnosed obesity,
and type 2 diabetes
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided
by height in meters squared); CPRD, Clinical Practice Research Datalink; HES,
Hospital Episode Statistics; IMD, Index of Multiple Deprivation; ONS, Office for
National Statistics.
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Outcomes
We investigated the association between atopic eczema and
cancer, overall and the site-specific cancers (Figure 2), cho-
sen a priori because they are common or were previously as-
sociated with atopic eczema or atopy.5 Overall cancer ex-
cluded NMSCs because of possible ascertainment bias (frequent
skin examinations in atopic eczema) and possible poor cap-
ture because NMSCs may be treated topically (eg, photody-
namic therapy) without histological confirmation.40 We ex-
cluded cutaneous lymphomas from lymphoma definitions to
reduce ascertainment bias because of frequent skin examina-
tions or misdiagnosis of cutaneous lymphoma as eczema. In
site-specific cancer analyses, we censored individuals at di-
agnosis of any cancer (excluding NMSC) and additionally at first
NMSC diagnosis in skin cancer analyses.
Covariates
We considered the following variables as potential confound-
ers: age, sex, calendar period, and socioeconomic status. In En-
gland, we used the Index of Multiple Deprivation (IMD) as a
measure of socioeconomic deprivation of residential
neighborhood.41-43 In Denmark, we used highest educational
level, partner status, and gross personal income as measures
of socioeconomic status.
Also considered were factors potentially on the pathway
between atopic eczema and cancer (ie, potential mediators),
specifically body mass index (BMI), smoking, and harmful al-
cohol use (in England). Data on these variables were not avail-
able in Denmark; we relied instead on diagnoses or treat-
ments for diseases associated with lifestyle factors as proxies,
including chronic obstructive pulmonary disease, hyperlip-
idemia, hypertension, alcohol-related conditions, ischemic
heart disease, hospital-diagnosed obesity, and type 2
diabetes.
Statistical Analysis
Main Analysis
We considered descriptive characteristics for individuals with
and without atopic eczema. We used Cox proportional haz-
ards regression, stratified by matched set, to estimate hazard
ratios (HRs) comparing overall cancer risk and risk of specific
cancers in people with and without atopic eczema.
Figure 1. Two Matched Cohorts of People With vs Without Atopic Eczema in England and Denmark
Exit
March 31, 2016January 2, 1998
January 1, 1982 June 30, 2016
Cohort entry
Eligible
Age ≥18 y
1 y From registration with a CPRD practice eligible for
 linkage with HES and ONS data
Date primary care practice met CPRD quality control
 standards
Study start (January 2, 1998)
No history of cancer
Eligible for cohort entry from the latest of
Death
Left practice
Last data collection from practice
Cancer diagnosis (any cancer, excluding nonmelanoma)
End of study (March 31, 2016)
Matched cohort only:  first atopic eczema diagnosisa
Follow-up ends at the earliest of
Enter cohort at the latest of
Eligible for cohort entry
Twelve months from date of eczema diagnosis  (based
 on 1x diagnostic code and 2x therapy records on
 separate days)
Cohort with atopic eczema
Enter cohort on the same day as matched individual with
 atopic eczema (matched on age, sex, and primary care
 practice, without replacement in calendar date order)
 No history of an atopic eczema diagnosis
Matched cohort without atopic eczema
England
Denmark
12-mo Registration
Exit
Cohort entry
Eligible
Born in Denmark
Living in Denmark
No age limits
No history of cancer
Eligible for cohort entry if
Death
No longer living in Denmark
Cancer diagnosis (any cancer, excluding nonmelanoma)
End of study (June 30, 2016)
Follow-up ends at the earliest of
Enter cohort at first hospital diagnosis of atopic eczema
(recorded as part of a hospital admission or outpatient
appointment)
Cohort with atopic eczema
Enter cohort on the same day as matched individual with
atopic eczema (matched on birth year and sex, with 
replacement)
No history of a previous atopic eczema diagnosis
Matched cohort without atopic eczema
CPRD indicates Clinical Practice
Research Datalink; HES, Hospital
Episode Statistics; and ONS, Office
for National Statistics.
a In England, individuals from the
matched cohort without atopic
eczema were censored if they had a
diagnosis of atopic eczema and
were then included in the atopic
eczema cohort if they had 2 records
for atopic eczema therapies.
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Figure 2. Associations Between Atopic Eczema and Cancer Outcomes in England and Denmark
in People With vs Without Atopic Eczema
0.25 1 40.50 2
HR (99% CI)
9
736
89
121
44
567
567
513
19
825
825
772
26
103
103
93
14
693
693
644
31
382
382
353
333
333
305
17
831
831
787
52
No. of
events
in atopic
eczema
cohort
24 402
24 402
22 690
2527
2527
2305
3468
3468
3267
2993
2993
2842
7555
7555
7151
276
3
4
4
4
4
2
5
1
3
8
Absolute rate
in atopic
eczema cohort
per 100 000
PYAR
852
852
894
115
88
88
91
14
203
203
205
37
260
260
302
14
20
20
20
29
29
30
24
24
25
13
13
14
12
12
12
29
29
31
271
271
290
43
Absolute
rate
difference
per 100 000
PYAR
33
33
18
5
7
7
2
4
–2
–2
–4
–1
15
15
9
1
0
0
–1
1
5
5
5
1
1
1
1
1
2
2
2
0
1
1
2
0
0
0
0
–1
–1
–1
–1
–5
25
27
22
6
HR (99% CI)
1.04 (1.02-1.06)
1.04 (1.02-1.06)
1.02 (0.99-1.04)
1.05 (0.95-1.16)
1.08 (1.02-1.16)
1.08 (1.01-1.16)
1.02 (0.95-1.10)
1.45 (1.08-1.96)
0.99 (0.93-1.04)
0.99 (0.94-1.04)
0.98 (0.92-1.03)
0.97 (0.76-1.24)
1.06 (1.00-1.12)
1.06 (1.00-1.13)
1.03 (0.97-1.10)
1.06 (0.70-1.60)
0.99 (0.87-1.14)
0.99 (0.86-1.14)
0.96 (0.83-1.11)
1.62 (0.85-3.09)
1.19 (1.07-1.34)
1.20 (1.07-1.34)
1.18 (1.04-1.33)
1.31 (0.76-2.26)
1.48 (1.07-2.04)
1.48 (1.07-2.04)
1.54 (1.08-2.20)
1.35 (0.65-2.82)
1.08 (0.96-1.23)
1.09 (0.96-1.23)
1.07 (0.94-1.22)
1.04 (0.64-1.71)
1.09 (0.93-1.29)
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Cancer
Overall
ENG minimally adj
ENG confounder adj
ENG mediator adj
DK minimally adj
ENG minimally adj
ENG confounder adj
ENG mediator adj
DK minimally adj
Lung
ENG minimally adj
ENG confounder adj
ENG mediator adj
DK minimally adj
Breasta
ENG minimally adj
ENG confounder adj
ENG mediator adj
DK minimally adj
Prostatea
ENG minimally adj
ENG confounder adj
ENG mediator adj
DK minimally adj
Pancreas
ENG minimally adj
ENG confounder adj
ENG mediator adj
DK minimally adj
Non-Hodgkin lymphoma
ENG minimally adj
ENG confounder adj
ENG mediator adj
DK minimally adj
Hodgkin lymphoma
ENG minimally adj
ENG confounder adj
ENG mediator adj
DK minimally adj
Leukemia
ENG minimally adj
ENG confounder adj
ENG mediator adj
DK minimally adj
Multiple myeloma
ENG minimally adj
ENG confounder adj
ENG mediator adj
DK minimally adj
Central nervous system cancers
ENG minimally adj
ENG confounder adj
ENG mediator adj
DK minimally adj
Melanoma
ENG minimally adj
ENG confounder adj
ENG mediator adj
DK minimally adj
Nonmelanoma skin cancer
All models implicitly adjusted for sex,
primary care practice (England [ENG]
only) and date at cohort entry
(because of stratification by matched
set), and age (because of the
underlying timescale). Confounders:
Index of Multiple Deprivation (IMD)
and calendar period. Potential
mediators: body mass index,
smoking, and harmful alcohol use.
Adj indicates adjusted; DK, Denmark;
HR indicates hazard ratio; and PYAR,
person-years at risk.
a Analysis of breast cancer was
limited to women. Analysis of
prostate cancer was limited to men.
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In England, we used age as the underlying timescale. In Den-
mark, because those with atopic eczema entered the cohort
at first hospital atopic eczema diagnosis, we used time since
first atopic eczema diagnosis for individuals with atopic ec-
zema and the corresponding cohort entry date for matched in-
dividuals.
The minimally adjusted models implicitly accounted for
matching and timescale factors, including age, sex, cohort en-
try date, and (in England only) primary care practice. In En-
gland, we followed with sequential models adjusting for (1) con-
founders (IMD and calendar period) to estimate the potential
association between atopic eczema and cancer and then (2) po-
tential mediators that might be on the pathway between atopic
eczema and cancer. Sequential models, adjusting first for con-
founders and then for potential mediators, allowed us to dif-
ferentiate between possible direct (eg, inflammatory) and in-
direct (ie, via mediating variables [eg, lifestyle factors])
associations of atopic eczema with cancer.44 In Denmark, we
were only able to adjust for potential confounders (ie, socio-
economic status) in sensitivity analyses restricted to individu-
als 30 years or older at cohort entry (socioeconomic status may
be unreliable in younger people, who are less likely to have at-
tained their highest educational level and have partner sta-
tus and gross personal income recorded).
We repeated our main analyses in a series of sensitivity
analyses assessing the robustness of our findings. Details are
listed in eTable 1 in Supplement 3.
Secondary Analyses
In our secondary analyses, we investigated whether the asso-
ciation between atopic eczema and cancer was (1) more pro-
nounced in individuals with severe or active atopic eczema (un-
feasible in Denmark because of small event numbers) and (2)
modified by age, sex, or presence of asthma. Details are avail-
able in eAppendix 3 in Supplement 3.
We assessed the proportional hazards assumption using
Schoenfeld residual plots. In all analyses, as per our ap-
proved protocols (listed in the Methods section), we used 99%
CIs to reduce the risk of type I error in the context of multiple
analyses.45 For data management and analyses, Stata, ver-
sion 15 (StataCorp LLC), and SAS, version 9.4 (SAS Institute Inc),
were used.
Results
In England, 2 629 640 individuals remained in valid matched
sets and were included in analyses (eFigure 1 and eTable 2 in
Supplement 3). The matched cohorts in England included
471 970 individuals with atopic eczema (median [IQR] age, 41.1
[24.9-60.7] years; 276 510 [58.6%] female) and 2 239 775 indi-
viduals without atopic eczema (median [IQR] age, 39.8 [25.9-
58.4] years; 1 301 074 [58.1%] female).
In Denmark, 490 618 individuals remained in valid
matched sets and were included in the analyses (eFigure 2 in
Supplement 3). The Danish matched cohorts included 44 945
individuals with atopic eczema (median [IQR] age, 13.7 [1.7-
21.1] years; 22 826 [50.8%] female) and 445 673 individuals
without atopic eczema (median [IQR] age, 13.5 [1.7-20.8] years;
226 323 [50.8%] female).
In England, the median follow-up was 4.5 years (IQR, 1.7-
9.0 years). The cohorts with and without atopic eczema had
broadly similar age, sex, and IMD (Table 2). Prevalence of smok-
ing or overweight/obesity was higher in individuals with atopic
eczema than in those without (46.7% vs 43.5% for smoking and
44.6% vs 40.7% for overweight/obesity). However, smoking
and BMI data were less likely to be missing in people with atopic
eczema compared with those without, and those with miss-
ing BMI or smoking status were more likely to be young and
male (eTable 2 in Supplement 3).
In Denmark, the median follow-up was 14.3 years (IQR, 6.3-
20.8 years). Distribution of age and sex was equal, and comor-
bidities at baseline were rare in both groups (Table 2). Among
individuals aged 30 years at cohort entry, higher educational
level and being single were more common in those with atopic
eczema (eTable 3 in Supplement 3) than in those without atopic
eczema.
Main Analysis
In both countries, little evidence was found of any associa-
tion between atopic eczema and overall cancer (Figure 2 and
eTable 4 and eTable 5 in Supplement 3). Hazard ratios (HRs)
comparing cancer risks in people with and without atopic ec-
zema were close to 1, showing evidence of only a minor, clini-
cally unimportant increase in minimally adjusted estimates
(HR, 1.05; 99% CI, 0.95-1.16 in Denmark) and confounder-
adjusted estimates (HR, 1.04; 99% CI, 1.02-1.06 in England).
After further adjusting for potential mediators, estimates
moved slightly closer to the null. For all specific cancer sites,
only small differences in absolute cancer risk were seen be-
tween individuals with and without atopic eczema.
For most site-specific cancers, English and Danish analy-
ses showed no strong evidence of an association with atopic
eczema (Figure 2). For the following cancers, HRs comparing
cancer risk in people with and without atopic eczema were
close to the null: breast, prostate, pancreas, leukemia, mul-
tiple myeloma, and central nervous system cancers. There were
decreases in melanoma risk and small increases in NMSC risk.
We found evidence of larger increases in lymphoma risk
in people with atopic eczema compared with those without
atopic eczema. In England, non-Hodgkin lymphoma (NHL) risk
was 20% higher (HR, 1.20; 99% CI, 1.07-1.34) and Hodgkin lym-
phoma risk was 48% higher (HR, 1.48; 99% CI, 1.07-2.04) in
people with atopic eczema compared with those without atopic
eczema after adjusting for confounders (Figure 2). Although
Danish point estimates for lymphoma were less precise than
English estimates, they showed similar increased risk (mini-
mally adjusted HR, 1.31; 99% CI, 0.76-2.26 for NHL and 1.35;
99% CI, 0.65-2.82 for Hodgkin lymphoma), but the 99% CIs
were wide.
An initial small increased lung cancer risk was observed
in people with atopic eczema vs those without (confounder-
adjusted HR, 1.08; 99% CI, 1.01-1.16 in England and mini-
mally adjusted HR, 1.45; 99% CI, 1.08-1.96 in Denmark)
(Figure 2). However, risk attenuated after further adjusting for
potential mediators (including smoking or smoking-related
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disease) (HR, 1.02; 99% CI, 0.95-1.10 in England and 1.21; 99%
CI, 0.88-1.65 in Denmark) (eTable 5 in Supplement 3).
Our sensitivity analyses yielded similar results (includ-
ing analyses restricted to individuals with a 3-year cancer-
free window after eczema diagnosis to limit reverse causality
as an explanation for our findings). These results are summa-
rized in eTable 6 and eTable 7 in Supplement 3.
Atopic Eczema Severity
In England, we generally found no evidence of different over-
all cancer or site-specific cancer risk in severe eczema (Figure 3
and eTable 8 in Supplement 3). An exception was lymphoma,
particularly NHL, for which the observed increased risk
became more pronounced with increasing eczema severity. The
NHL confounder-adjusted HRs compared with those without
atopic eczema were 1.06 (99% CI, 0.90-1.25) for mild eczema,
1.24 (99% CI, 1.04-1.48) for moderate eczema, and 2.08 (99%
CI, 1.42-3.04) for severe eczema (eTable 8 in Supplement 3).
Atopic Eczema Activity
In England, we saw limited evidence of an association be-
tween atopic eczema activity and most site-specific cancers
(eFigure 3 and eTable 9 in Supplement 3). Notably, there were
higher risks of NHL in people with more active atopic eczema
(confounder-adjusted HR compared with those with no atopic
eczema, 1.07; 99% CI, 0.83-1.38 for never active eczema; 1.08;
Table 2. Characteristics of the English and Danish Study Populations at Cohort Entrya
Variable
England Denmark
With atopic eczema
(n = 471 970)
Without atopic
eczema
(n = 2 239 775)
With atopic eczema
(n = 44 945)
Without atopic
eczema (n = 445 673)
Follow-up
Total person-years 2 864 446 12 601 393 639 121 6 358 286
Duration of follow-up,
median (IQR), y
4.8 (1.9-9.2) 4.2 (1.7-8.6) 14.3 (6.3-20.8) 14.3 (6.3-20.8)
Female sex 276 510 (58.6) 1 301 074 (58.1) 22 826 (50.8) 226 323 (50.8)
Age, y
<18 NA NA 31 772 (70.2) 316 396 (71.0)
18-44 262 119 (55.5) 1 292 565 (57.7) 9875 (22.0) 98 181 (22.0)
45-64 115 510 (24.5) 563 375 (25.2) 2418 (5.4) 23 308 (5.2)
≥65 94 341 (20.0) 383 835 (17.1) 880 (2.0) 7788 (1.7)
IMD quintileb
1, Least deprived 113 598 (24.1) 531 707 (23.7) NA NA
2 107 613 (22.8) 509 274 (22.7) NA NA
3 92 864 (19.7) 441 451 (19.7) NA NA
4 90 112 (19.1) 428 193 (19.1) NA NA
5, Most deprived 67 783 (14.4) 329 150 (14.7) NA NA
BMIc
Underweight, <20 34 065 (7.2) 165 212 (7.4) NA NA
Normal, 20-24 153 822 (32.6) 721 037 (32.2) NA NA
Overweight, 25-29 127 144 (26.9) 570 179 (25.5) NA NA
Obese, ≥30 83 169 (17.6) 341 122 (15.2) NA NA
Missing 73 770 (15.6) 442 225 (19.7) NA NA
Smokingc
Nonsmoker 239 072 (50.7) 1 132 798 (50.6) NA NA
Current smoker or
ex-smoker
220 331 (46.7) 975 355 (43.5) NA NA
Missing 12 567 (2.7) 131 622 (5.9) NA NA
Harmful alcohol used 12 812 (2.7) 49 844 (2.2) NA NA
Lifestyle-related diseases
Chronic obstructive
pulmonary disease
NA NA 555 (1.2) 1568 (0.4)
Hyperlipidemia NA NA 533 (1.2) 4389 (1.0)
Hypertension NA NA 2012 (4.5) 16 601 (3.7)
Alcohol-related
conditions
NA NA 591 (1.3) 4747 (1.1)
Ischemic heart disease NA NA 274 (0.6) 2011 (0.5)
Hospital-diagnosed
obesity
NA NA 474 (1.1) 3733 (0.8)
Type 2 diabetes NA NA 248 (0.6) 2325 (0.5)
Abbreviations: BMI, body mass index
(calculated as weight in kilograms
divided by height in meters squared);
IMD, Index of Multiple Deprivation;
IQR, interquartile range; NA, not
applicable.
a Unless otherwise specified, data are
given as No. (%). Individuals could
contribute data as both atopic
eczema exposed and unexposed.
Further characteristics for the
English study population (including
ethnicity and comorbidities) for the
overall cohort, individuals included
in the model additionally adjusting
for potential mediators (ie, with no
missing BMI or smoking status
data), and for individuals with
missing BMI or smoking status data
are listed in eTable 2 in
Supplement 3. Further
characteristics for the Danish study
population and socioeconomic
variables (highest educational level,
partner status, and gross personal
income) among those 30 years or
older are listed in eTable 3 in
Supplement 3.
b Based on individual-level data (from
2007) if available, supplemented
with practice-level data (from 2010)
if individual-level data were not
available.
c Based on records closest to the
index date.
d Based on records on or before
cohort entry. We defined harmful
alcohol use based on primary care
morbidity codes suggesting harmful
or heavy alcohol use (including
alcohol dependency codes and
codes associated with physical or
psychological harm associated with
alcohol use) or a prescription for
drugs used to maintain abstinence
(acamprosate calcium, disulfiram, or
nalmefene hydrochloride).
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99% CI, 0.92-1.26 for moderately active eczema; and 1.58; 99%
CI, 1.28-1.94 for very active eczema) and higher overall can-
cer risk in people with more active eczema (confounder-
adjusted HR, 1.11; 99% CI, 1.07-1.15) (eTable 9 in Supple-
ment 3).
Effect Modification
Little evidence was found of effect modification by age, sex,
or presence of asthma. These results are summarized in
eTables 10, 11, 12, 13, 14, and 15 in Supplement 3.
Discussion
In 2 matched cohort studies from England and Denmark, no
evidence was found of an association between atopic
eczema and most cancers. However, increased risk of lym-
phoma, particularly NHL, was seen among people with
atopic eczema, specifically those with more severe or active
disease. In England, we observed a 23% increased risk of
lymphoma overall (similar to Danish estimates), with a
Figure 3. In England, Comparison of Cancer Rates at Each Level of Eczema Severity
in People With vs Without Atopic Eczema
Cancer
Overall
Mild eczema
Moderate eczema
Severe eczema
Lung
Moderate eczema
Severe eczema
Breast
Mild eczema
Mild eczema
Severe eczema
Prostate
Mild eczema
Moderate eczema
Moderate eczema
Pancreas
Mild eczema
Moderate eczema
Severe eczema
Severe eczema
Mild eczema
Moderate eczema
Severe eczema
Leukemia
Hodgkin lymphoma
Mild eczema
Moderate eczema
Severe eczema
Non-Hodgkin lymphoma
Moderate eczema
Severe eczema
Multiple myeloma
Mild eczema
Mild eczema
Severe eczema
Central nervous system cancers
Mild eczema
Moderate eczema
Moderate eczema
Melanoma
Mild eczema
Moderate eczema
Severe eczema
Severe eczema
0.5 21 4
HR (99% CI)
Additionally adjusted
for potential mediators
Fully adjusted for IMD
and calendar period
0.5 21 4
HR (99% CI)
0.5 21 4
HR (99% CI)
Minimally
adjusted
Estimated hazard ratios are from Cox
proportional hazards regression with
current age as the underlying
timescale, stratified by matched set
(matched on age at cohort entry, sex,
primary care practice, and date at
cohort entry). All models were fitted
to individuals with complete data for
all variables included in each model
and from valid matched sets,
including 1 individual with atopic
eczema and at least 1 individual
without atopic eczema. All models
implicitly adjusted for sex, primary
care practice, and date at cohort
entry because of stratification by
matched set and for age because of
the underlying timescale. Fifty-two
percent of those with severe eczema
were classified as having severe
eczema based on a prescription for
systemic drugs, 1.5% based on a
record for phototherapy, 28.0% due
to specialist dermatology referral,
and 18.0% as a result of a hospital
admission for atopic eczema.
Potential mediators were body mass
index, smoking, and harmful alcohol
use. Specific central nervous system
tumors (meningioma, brain
neoplasm, and others) were too rare
to consider individually. HR indicates
hazard ratio; IMD, Index of Multiple
Deprivation. Population counts are
listed in eTable 4 and eTable 5 in
Supplement 3.
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100% increase in NHL risk in people with severe eczema,
although absolute risk differences were small.
Findings in Context
A recent systematic review and meta-analysis12 of cancer
risk in people with atopic eczema highlighted the heteroge-
neity and limitations of existing data. Overall, our findings
generally confirm those reported in prior smaller
studies.12,14,16,19,23,46-54
Our study is one of the few longitudinal studies12,14,16,23,
46,47,52 to adjust for numerous potential confounders and me-
diators and to address the role of eczema severity and activ-
ity in 2 cohorts with complementary strengths and limita-
tions. Our results suggest that the overall cancer risk among
individuals with atopic eczema is small. This baseline risk is
particularly important to establish as many new immuno-
modulatory systemic therapeutics are brought to market.
Previous studies assessing the association between atopic
eczema and site-specific cancers have had conflicting results.12
A discussion follows for brain cancer, solid-organ cancers,
melanoma, and noncutaneous lymphomas.
Brain Cancer
A recent systematic review and meta-analysis46 reported a 23%
reduction in brain cancer risk in people with atopic eczema.
However, this protective association was not observed with
more specific atopic eczema diagnostic criteria, and there was
substantial heterogeneity (I2 > 75%) between studies. We could
not reliably assess the risk of brain cancer subtypes because
of low statistical power.
Solid-Organ Cancers
Some prior cohort and case-control studies47-51 that
assessed other solid-organ cancers found an increased risk
of lung cancer associated with atopic diseases. Although we
initially observed a small increased lung cancer risk in indi-
viduals with atopic eczema, this association disappeared
after adjusting for possible mediators, suggesting that the
increased risk may be attributable to smoking among people
with atopic eczema.
Melanoma
The observation of a potentially protective association of
atopic eczema with melanoma is of interest. Our findings
are consistent with observations from mouse models21 and
may reflect sun avoidance in people with atopic eczema or
increased immune surveillance (further studies would be
required to elucidate biologic mechanisms). Having
atopic eczema might have led to more skin examinations,
resulting in ascertainment bias and either an increased skin
cancer risk (as seen for NMSC in this study and in other
studies23,47,51,52) or an apparently decreased risk because of
better detection of melanoma in situ (with consequent
lower invasive cancer risk). If ascertainment leads to
increased melanoma detection, we would expect to see an
even larger risk reduction in advanced melanoma; addi-
tional studies could examine this hypothesis.
Noncutaneous Lymphomas
The association between atopic eczema and lymphoma is con-
sistent with previous findings in a systematic review and
meta-analysis16 of an overall relative risk of lymphoma of 1.43,
as well as the finding in a CPRD-based case-control study19 of
an association between Hodgkin lymphoma and allergic dis-
ease (asthma, eczema, and allergic rhinitis). The association
of eczema severity with lymphoma has previously been as-
sessed in only 1 cohort study55 and 2 case-control studies.53,54
Although the cohort study55 used data from Medicaid, a US ad-
ministrative database, and focused on psoriasis, it demon-
strated a 2-fold increased lymphoma risk among individuals
with severe eczema in a limited secondary analysis. How-
ever, because NHL and Hodgkin lymphoma have different risk
factor profiles,56 our findings in this study might suggest de-
tection bias (because of the use of chest radiographs in people
with comorbid asthma) or residual confounding, perhaps be-
cause of immunosuppression57 (although sensitivity analy-
ses adjusting for immunosuppression in the present study were
similar to our main analysis results).
Previous studies attempting to clarify whether topical cal-
cineurin inhibitors (used in our study to identify moderate ec-
zema severity) increase lymphoma risk in people with atopic
eczema have failed to convincingly demonstrate an associa-
tion, although most analyses were limited by low statistical
power and confounding by severity.16 A low proportion of in-
dividuals with atopic eczema treated in primary care receive
calcineurin inhibitors because these agents are recom-
mended for specialist use only.58
Implications for Future Research
In this study, we found an increased lymphoma risk in indi-
viduals with atopic eczema, especially for those with severe
eczema; however, absolute differences were small, and there
was little evidence of an increased risk of other cancers. This
finding may be because of reverse causation (ie, atopic ec-
zema could be an early sign of lymphoma), but a sensitivity
analysis extending the cancer-free lag period to 3 years did not
show any evidence of this hypothesis (eTable 6 in Supple-
ment 3). Future research could explore underlying mecha-
nisms for the associations observed for lymphoma, particu-
larly NHL, including studies assessing Epstein-Barr virus in
people with atopic eczema, as well as addressing the thera-
peutic implications (associated with existing and novel im-
munosuppressive treatments) of our findings in individuals
with severe eczema.
Strengths and Limitations
This study has strengths and limitations. A major strength of
this study is the use of prospectively collected data from large
representative population-based databases from 2 countries
with free health care access.26,30,59 Our results reflect real-
world clinical practice and are likely to be generalizable to other
settings. Although the Danish findings are unlikely to apply to
individuals with mild eczema because the Danish data were
restricted to hospital-based atopic eczema diagnoses, the Dan-
ish results are consistent with those for individuals with mod-
erate to severe eczema in England. Therefore, combining the
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English and Danish population-based data lends credence to
the study conclusions by virtue of triangulation.60
It is possible that atopic eczema was misclassified in our
study. Although we used a validated algorithm to identify
atopic eczema in England and the validity of diagnoses in a der-
matology department was found to be high in Denmark (posi-
tive predictive value, 99%61), we may have missed atopic ec-
zema diagnoses (likely unrelated to cancer risk), which could
have underestimated the magnitude of any association be-
tween atopic eczema and cancer.
The quality of diagnoses in the Danish Cancer Registry is
excellent: reporting is mandatory, diagnoses stem from a range
of sources, the proportion of histologically verified tumors is
high (>90% for major cancers), and few diagnoses are based
only on death certificates (0.1%).32,62,63 In England, most na-
tionally registered cancer cases (>90%) can be identified in the
CPRD; by including the HES and ONS data, we further im-
proved cancer identification.64 Nevertheless, we cannot ex-
clude ascertainment bias; cancers may be diagnosed more fre-
quently in individuals with atopic eczema because of frequent
skin examinations for skin cancer, regular blood test monitor-
ing for systemic immunosuppressive drugs (in severe ec-
zema only), or chest radiographs for concomitant asthma or
before drug initiation in severe eczema (eg, cyclosporine).
Potential misclassification of covariates may have led to
residual confounding, biasing the estimates of direct associa-
tions in mediation analyses. However, increasing adjustment
made little change to our HR estimates. In Denmark, we were
only able to adjust for potential confounders (ie, socioeco-
nomic status) in sensitivity analyses, but the results of these
sensitivity analyses were similar to those of the main analy-
sis. However, matching with replacement in the Danish co-
hort may have resulted in mild misleadingly narrow 99% CIs.
A limitation that is common to many dermatological con-
ditions lacking quantitative measures is reliance on treat-
ments to classify disease severity and activity. In Denmark,
sample sizes were insufficient for eczema severity and activ-
ity analyses; however, we note that, by definition, most indi-
viduals had moderate to severe eczema. Atopic eczema was
identified in hospital records because we had no access to data
from Danish primary care, where mild eczema is managed. The
study also had limited power to examine certain cancers, spe-
cifically brain cancer subtypes.
Conclusions
In this study, no evidence was found that people with atopic
eczema are at increased risk of most cancers. An exception is
the observed association between atopic eczema and lym-
phoma, particularly NHL, that increased with eczema sever-
ity. This finding warrants further study as new immunomodu-
latory systemic therapeutics are brought to market that may
alter cancer risk.
ARTICLE INFORMATION
Accepted for Publication: April 28, 2020.
Published Online: June 24, 2020.
doi:10.1001/jamadermatol.2020.1948
Open Access: This is an open access article
distributed under the terms of the CC-BY License.
© 2020 Mansfield KE et al. JAMA Dermatology.
Author Affiliations: Department of
Non-communicable Disease Epidemiology, London
School of Hygiene and Tropical Medicine, London,
United Kingdom (Mansfield, Mulick, Wong, Smeeth,
Bhaskaran, dos Santos Silva, Langan); Department
of Clinical Epidemiology, Aarhus University
Hospital, Aarhus N, Denmark (Schmidt, Darvalics,
Sørensen); Department of Dermatology, Aarhus
University Hospital, Aarhus N, Denmark (Schmidt);
Department of Dermatology, University of
California, San Francisco (Abuabara); Department
of Medical Statistics, London School of Hygiene and
Tropical Medicine, London, United Kingdom
(Silverwood); Centre for Longitudinal Studies,
Department of Social Science, University College
London, London, United Kingdom (Silverwood);
Health Data Research UK, London, United Kingdom
(Langan).
Author Contributions: Drs Mansfield and Schmidt
had full access to all of the data in the study and
take responsibility for the integrity of the data and
the accuracy of the data analysis. Drs Mansfield and
Schmidt contributed equally as co–first authors.
Concept and design: Mansfield, Schmidt, Darvalics,
Abuabara, Smeeth, Bhaskaran, Langan.
Acquisition, analysis, or interpretation of data:
All authors.
Drafting of the manuscript: Mansfield, Schmidt.
Critical revision of the manuscript for important
intellectual content: All authors.
Statistical analysis: Mansfield, Darvalics,
Mulick, Silverwood.
Obtained funding: Schmidt, Langan.
Administrative, technical, or material support:
Mansfield, Sørensen, Bhaskaran.
Supervision: Schmidt, Abuabara, Sørensen, Smeeth,
Bhaskaran, Langan.
Conflict of Interest Disclosures: Dr Mansfield and
Ms Mulick reported being funded under a Wellcome
Trust grant awarded to Dr Langan. Dr Abuabara
reported receiving personal fees from
TARGET-DERM and receiving grants from Pfizer.
Dr Sørensen reported that the Department of
Clinical Epidemiology, Aarhus University Hospital,
receives funding for other studies from companies
in the form of research grants to (and administered
by) Aarhus University. Dr Smeeth reported
receiving grants from the Wellcome Trust, Medical
Research Council, National Institute for Health
Research, GlaxoSmithKline, British Heart
Foundation, and Diabetes UK and being a trustee of
the British Heart Foundation. Dr Bhaskaran
reported receiving grants from the Wellcome Trust,
Royal Society, Medical Research Council, British
Heart Foundation, and Diabetes UK. Dr Langan
reported receiving grants from the Wellcome Trust
and from IMI Horizon 2020 funding BIOMAP. No
other disclosures were reported.
Funding/Support: Dr Bhaskaran was supported by
a Sir Henry Dale Fellowship from the Wellcome
Trust and the Royal Society (107731/Z/15/Z). Dr
Langan was supported by a Wellcome Trust Senior
Clinical Fellowship (205039/Z/16/Z). The Danish
study was funded by the Dagmar Marshalls Fund
and the Aase and Ejnar Danielsens Fund.
Role of the Funder/Sponsor: The funders had no
role in the design and conduct of the study;
collection, management, analysis, and
interpretation of the data; preparation, review, or
approval of the manuscript; and decision to submit
the manuscript for publication.
Additional Information: This article used data
provided by patients and collected by the United
Kingdom National Health Service as part of their
care and support.
REFERENCES
1. Barbarot S, Auziere S, Gadkari A, et al.
Epidemiology of atopic dermatitis in adults: results
from an international survey. Allergy. 2018;73(6):
1284-1293. doi:10.1111/all.13401
2. Silverberg JI, Hanifin JM. Adult eczema
prevalence and associations with asthma and other
health and demographic factors: a US
population–based study. J Allergy Clin Immunol.
2013;132(5):1132-1138. doi:10.1016/j.jaci.2013.08.031
3. Hay RJ, Johns NE, Williams HC, et al. The global
burden of skin disease in 2010: an analysis of the
prevalence and impact of skin conditions. J Invest
Dermatol. 2014;134(6):1527-1534. doi:10.1038/jid.
2013.446
4. Asher MI, Montefort S, Björkstén B, et al; ISAAC
Phase Three Study Group. Worldwide time trends in
the prevalence of symptoms of asthma, allergic
rhinoconjunctivitis, and eczema in childhood:
ISAAC Phases One and Three repeat multicountry
cross-sectional surveys [published correction
appears in Lancet. 2007;370(9593):1128]. Lancet.
Association Between Atopic Eczema and Cancer in England and Denmark Original Investigation Research
jamadermatology.com (Reprinted) JAMA Dermatology October 2020 Volume 156, Number 10 1095
Downloaded From: https://jamanetwork.com/ on 11/11/2020
2006;368(9537):733-743. doi:10.1016/S0140-6736
(06)69283-0
5. Deckert S, Kopkow C, Schmitt J. Nonallergic
comorbidities of atopic eczema: an overview of
systematic reviews. Allergy. 2014;69(1):37-45.
doi:10.1111/all.12246
6. Wedgeworth E, Powell AM, Flohr C. Eczema and
cancer risk: a critical appraisal and review of the
literature. Br J Dermatol. 2011;165(3):457-462.
doi:10.1111/j.1365-2133.2011.10542.x
7. Sørensen HT, Mellemkjaer L, Nielsen GL, Baron
JA, Olsen JH, Karagas MR. Skin cancers and
non-Hodgkin lymphoma among users of systemic
glucocorticoids: a population-based cohort study.
J Natl Cancer Inst. 2004;96(9):709-711. doi:10.
1093/jnci/djh118
8. Naghavi M, Abajobir AA, Abbafati C, et al; GBD
2016 Causes of Death Collaborators. Global,
regional, and national age-sex specific mortality for
264 causes of death, 1980-2016: a systematic
analysis for the Global Burden of Disease Study
2016. Lancet. 2017;390(10100):1151-1210. doi:10.
1016/S0140-6736(17)32152-9
9. Schofield JK, Fleming D, Grindlay D, Williams H.
Skin conditions are the commonest new reason
people present to general practitioners in England
and Wales. Br J Dermatol. 2011;165(5):1044-1050.
doi:10.1111/j.1365-2133.2011.10464.x
10. Moth G, Vedsted P, Olesen F. The Pattern of
Contact and Illness in General Practice: KOS 2008 [in
Danish]. Forskningsenheden for Almen Praksis; 2010.
11. Bosma AL, Spuls PI, Garcia-Doval I, et al.
Treatment of Atopic Eczema (TREAT) Registry
Taskforce: protocol for a European safety study of
dupilumab and other systemic therapies in patients
with atopic eczema. Br J Dermatol. Published online
August 24, 2019. doi:10.1111/bjd.18452
12. Wang L, Bierbrier R, Drucker AM, Chan AW.
Noncutaneous and cutaneous cancer risk in
patients with atopic dermatitis: a systematic review
and meta-analysis. JAMA Dermatol. Published online
December 11, 2019. doi:10.1001/jamadermatol.2019.
3786
13. Burki TK. Association between allergies and
reduced risk of glioma. Lancet Oncol. 2016;17(3):e94.
doi:10.1016/S1470-2045(16)00087-5
14. Linos E, Raine T, Alonso A, Michaud D. Atopy
and risk of brain tumors: a meta-analysis. J Natl
Cancer Inst. 2007;99(20):1544-1550. doi:10.1093/
jnci/djm170
15. Wang M, Chen C, Qu J, et al. Inverse association
between eczema and meningioma: a meta-analysis.
Cancer Causes Control. 2011;22(10):1355-1363.
doi:10.1007/s10552-011-9808-6
16. Legendre L, Barnetche T, Mazereeuw-Hautier J,
Meyer N, Murrell D, Paul C. Risk of lymphoma in
patients with atopic dermatitis and the role of
topical treatment: a systematic review and
meta-analysis. J Am Acad Dermatol. 2015;72(6):
992-1002. doi:10.1016/j.jaad.2015.02.1116
17. Linabery AM, Jurek AM, Duval S, Ross JA.
The association between atopy and
childhood/adolescent leukemia: a meta-analysis.
Am J Epidemiol. 2010;171(7):749-764. doi:10.1093/
aje/kwq004
18. Margolis DJ, Abuabara K, Hoffstad OJ, Wan J,
Raimondo D, Bilker WB. Association between
malignancy and topical use of pimecrolimus. JAMA
Dermatol. 2015;151(6):594-599. doi:10.1001/
jamadermatol.2014.4305
19. Rafiq M, Hayward A, Warren-Gash C, et al.
Allergic disease, corticosteroid use and risk of
Hodgkin’s lymphoma: a United Kingdom
nationwide case-control study. J Allergy Clin Immunol.
2020;145(3):868-876. doi:10.1016/j.jaci.2019.10.033
20. Castellsague J, Kuiper JG, Pottegård A, et al.
A cohort study on the risk of lymphoma and skin
cancer in users of topical tacrolimus, pimecrolimus,
and corticosteroids (Joint European Longitudinal
Lymphoma and Skin Cancer Evaluation–JOELLE
study). Clin Epidemiol. 2018;10:299-310. doi:10.
2147/CLEP.S146442
21. Cipolat S, Hoste E, Natsuga K, Quist SR, Watt
FM. Epidermal barrier defects link atopic dermatitis
with altered skin cancer susceptibility. eLife. 2014;3:
e01888. doi:10.7554/eLife.01888
22. Margolis DJ, Hoffstad O, Bilker W. Lack of
association between exposure to topical calcineurin
inhibitors and skin cancer in adults. Dermatology.
2007;214(4):289-295. doi:10.1159/000100879
23. Jensen AO, Svaerke C, Körmendiné Farkas D,
Olesen AB, Kragballe K, Sørensen HT. Atopic
dermatitis and risk of skin cancer: a Danish
nationwide cohort study (1977-2006). Am J Clin
Dermatol. 2012;13(1):29-36. doi:10.2165/11593280-
000000000-00000
24. Cheng J, Zens MS, Duell E, Perry AE, Chapman
MS, Karagas MR. History of allergy and atopic
dermatitis in relation to squamous cell and basal cell
carcinoma of the skin. Cancer Epidemiol Biomarkers
Prev. 2015;24(4):749-754. doi:10.1158/1055-9965.
EPI-14-1243
25. Gandini S, Stanganelli I, Palli D, De Giorgi V,
Masala G, Caini S. Atopic dermatitis, naevi count
and skin cancer risk: a meta-analysis. J Dermatol Sci.
2016;84(2):137-143. doi:10.1016/j.jdermsci.2016.07.
009
26. Herrett E, Gallagher AM, Bhaskaran K, et al.
Data resource profile: Clinical Practice Research
Datalink (CPRD). Int J Epidemiol. 2015;44(3):827-836.
doi:10.1093/ije/dyv098
27. Mathur R, Bhaskaran K, Chaturvedi N, et al.
Completeness and usability of ethnicity data in
UK-based primary care and hospital databases.
J Public Health (Oxf). 2014;36(4):684-692. doi:10.
1093/pubmed/fdt116
28. Bhaskaran K, Forbes HJ, Douglas I, Leon DA,
Smeeth L. Representativeness and optimal use of
body mass index (BMI) in the UK Clinical Practice
Research Datalink (CPRD). BMJ Open. 2013;3(9):
e003389. doi:10.1136/bmjopen-2013-003389
29. NHS Digital. Hospital Episode Statistics (HES).
Accessed June 25, 2015. http://www.hscic.gov.uk/
hes
30. Schmidt M, Schmidt SAJ, Sandegaard JL,
Ehrenstein V, Pedersen L, Sørensen HT. The Danish
National Patient Registry: a review of content, data
quality, and research potential. Clin Epidemiol.
2015;7:449-490. doi:10.2147/CLEP.S91125
31. Schmidt M, Schmidt SAJ, Adelborg K, et al.
The Danish health care system and epidemiological
research: from health care contacts to database
records. Clin Epidemiol. 2019;11:563-591. doi:10.
2147/CLEP.S179083
32. Gjerstorff ML. The Danish Cancer Registry.
Scand J Public Health. 2011;39(7)(suppl):42-45.
doi:10.1177/1403494810393562
33. Schmidt M, Pedersen L, Sørensen HT. The
Danish Civil Registration System as a tool in
epidemiology. Eur J Epidemiol. 2014;29(8):541-549.
doi:10.1007/s10654-014-9930-3
34. Pottegård A, Schmidt SAJ, Wallach-Kildemoes
H, Sørensen HT, Hallas J, Schmidt M. Data resource
profile: the Danish National Prescription Registry.
Int J Epidemiol. 2017;46(3):798-798f. doi:10.1093/
ije/dyw213
35. Jensen VM, Rasmussen AW. Danish education
registers. Scand J Public Health. 2011;39(7)
(suppl):91-94. doi:10.1177/1403494810394715
36. Baadsgaard M, Quitzau J. Danish registers on
personal income and transfer payments. Scand J
Public Health. 2011;39(7)(suppl):103-105. doi:10.
1177/1403494811405098
37. London School of Hygiene and Tropical
Medicine. LSHTM data compass. Last modified
January 2020. Accessed May 25, 2020. https://
datacompass.lshtm.ac.uk/
38. Abuabara K, Magyari AM, Hoffstad O, et al.
Development and validation of an algorithm to
accurately identify atopic eczema patients in
primary care electronic health records from the UK.
J Invest Dermatol. 2017;137(8):1655-1662. doi:10.
1016/j.jid.2017.03.029
39. Heide-Jørgensen U, Adelborg K, Kahlert J,
Sørensen HT, Pedersen L. Sampling strategies for
selecting general population comparison cohorts.
Clin Epidemiol. 2018;10:1325-1337. doi:10.2147/
CLEP.S164456
40. Stefoski Mikeljevic J, Johnston C, Adamson PJ,
et al. How complete has skin cancer registration
been in the UK? a study from Yorkshire. Eur J Cancer
Prev. 2003;12(2):125-133. doi:10.1097/00008469-
200304000-00006
41. Deas I, Robson B, Wong C, Bradford M.
Measuring neighbourhood deprivation: a critique of
the Index of Multiple Deprivation. Environ Plann C
Gov Policy. 2003;21(6):883-903. doi:10.1068/c0240
42. Noble M, Wright G, Smith G, Dibben C.
Measuring multiple deprivation at the small-area
level. Environ Plann A. 2006;38(1):169-185. doi:10.
1068/a37168
43. Department for Communities and Local
Government. The English Indices of Deprivation
2015: frequently asked questions (FAQs). Updated
December 5, 2016. Accessed July 2019. https://
assets.publishing.service.gov.uk/government/
uploads/system/uploads/attachment_data/file/
579151/English_Indices_of_Deprivation_2015_-_
Frequently_Asked_Questions_Dec_2016.pdf
44. Lederer D, Bell S, Branson R, et al. Control of
confounding and reporting of results in causal
inference studies: guidance for authors from
editors of respiratory, sleep, and critical care
journals. Ann Am Thorac Soc. 2019;16(1):22-28.
doi:10.1513/AnnalsATS.201808-564PS
45. Ioannidis JPA. The proposal to lower P value
thresholds to .005. JAMA. 2018;319(14):1429-1430.
doi:10.1001/jama.2018.1536
46. Halling-Overgaard AS, Ravnborg N, Silverberg
JI, Egeberg A, Thyssen JP. Atopic dermatitis and
cancer in solid organs: a systematic review and
meta-analysis. J Eur Acad Dermatol Venereol. 2019;
33(2):e81-e82. doi:10.1111/jdv.15230
47. Hagströmer L, Ye W, Nyrén O, Emtestam L.
Incidence of cancer among patients with atopic
Research Original Investigation Association Between Atopic Eczema and Cancer in England and Denmark
1096 JAMA Dermatology October 2020 Volume 156, Number 10 (Reprinted) jamadermatology.com
Downloaded From: https://jamanetwork.com/ on 11/11/2020
dermatitis. Arch Dermatol. 2005;141(9):1123-1127.
doi:10.1001/archderm.141.9.1123
48. Wang H, Rothenbacher D, Löw M, Stegmaier C,
Brenner H, Diepgen TL. Atopic diseases,
immunoglobulin E and risk of cancer of the
prostate, breast, lung and colorectum. Int J Cancer.
2006;119(3):695-701. doi:10.1002/ijc.21883
49. Castaing M, Youngson J, Zaridze D, et al. Is the
risk of lung cancer reduced among eczema
patients? Am J Epidemiol. 2005;162(6):542-547.
doi:10.1093/aje/kwi241
50. Ruff S, Egeberg A, Andersen YMF, Gislason G,
Skov L, Thyssen JP. Prevalence of cancer in adult
patients with atopic dermatitis: a nationwide study.
Acta Derm Venereol. 2017;97(9):1127-1129. doi:10.
2340/00015555-2703
51. Olesen AB, Engholm G, Storm HH,
Thestrup-Pedersen K. The risk of cancer among
patients previously hospitalized for atopic
dermatitis. J Invest Dermatol. 2005;125(3):445-449.
doi:10.1111/j.0022-202X.2005.23839.x
52. Arana A, Wentworth CE, Fernández-Vidaurre C,
Schlienger RG, Conde E, Arellano FM. Incidence of
cancer in the general population and in patients
with or without atopic dermatitis in the U.K. Br J
Dermatol. 2010;163(5):1036-1043. doi:10.1111/j.1365-
2133.2010.09887.x
53. Arellano FM, Arana A, Wentworth CE,
Fernández-Vidaurre C, Schlienger RG, Conde E.
Lymphoma among patients with atopic dermatitis
and/or treated with topical immunosuppressants in
the United Kingdom. J Allergy Clin Immunol.
2009;123(5):1111-1116, 116.e1-116.e13. doi:10.1016/j.jaci.
2009.02.028
54. Arellano FM, Wentworth CE, Arana A,
Fernández C, Paul CF. Risk of lymphoma following
exposure to calcineurin inhibitors and topical
steroids in patients with atopic dermatitis. J Invest
Dermatol. 2007;127(4):808-816. doi:10.1038/sj.jid.
5700622
55. Margolis D, Bilker W, Hennessy S, Vittorio C,
Santanna J, Strom BL. The risk of malignancy
associated with psoriasis. Arch Dermatol. 2001;137
(6):778-783.
56. Cogliano VJ, Baan R, Straif K, et al. Preventable
exposures associated with human cancers. J Natl
Cancer Inst. 2011;103(24):1827-1839. doi:10.1093/
jnci/djr483
57. Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al.
Spectrum of cancer risk among US solid organ
transplant recipients. JAMA. 2011;306(17):1891-1901.
doi:10.1001/jama.2011.1592
58. Surveillance report 2016: atopic eczema in
under 12s: diagnosis and management (2007).
NICE guideline CG57. Published July 21, 2016.
Accessed July 2019. https://www.ncbi.nlm.nih.gov/
books/NBK552070/
59. Rothman KJ. Six persistent research
misconceptions. J Gen Intern Med. 2014;29(7):
1060-1064. doi:10.1007/s11606-013-2755-z
60. Lawlor DA, Tilling K, Davey Smith G.
Triangulation in aetiological epidemiology. Int J
Epidemiol. 2016;45(6):1866-1886. doi:10.1093/ije/
dyw314
61. Schmidt SAJ, Olsen M, Schmidt M, et al. Atopic
dermatitis and risk of atrial fibrillation or flutter:
a 35-year follow-up study. J Am Acad Dermatol.
Published online August 20, 2019. doi:10.1016/j.jaad.
2019.08.039
62. Pedersen SA, Schmidt SAJ, Klausen S, et al.
Melanoma of the skin in the Danish Cancer Registry
and the Danish Melanoma Database. Epidemiology.
2018;29(3):442-447. doi:10.1097/EDE.
0000000000000802
63. Friis S, Jørgensen T, Mellemkjær L. Validation of
the Danish Cancer Registry and Selected Clinical
Cancer Databases. Danish Cancer Society; 2012:1-2.
64. Boggon R, van Staa TP, Chapman M, Gallagher
AM, Hammad TA, Richards MA. Cancer recording
and mortality in the General Practice Research
Database and linked cancer registries.
Pharmacoepidemiol Drug Saf. 2013;22(2):168-175.
doi:10.1002/pds.3374
Association Between Atopic Eczema and Cancer in England and Denmark Original Investigation Research
jamadermatology.com (Reprinted) JAMA Dermatology October 2020 Volume 156, Number 10 1097
Downloaded From: https://jamanetwork.com/ on 11/11/2020
